ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Virginia » Hematology Oncology

Top Hematology Oncology Prescribers in Virginia

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
TIMOTHY BROTHERTON M,D,

Hematology Oncology

7,043

$1.65M

563
430 are 65+

12%
patients receiving schedule two controlled substances

Avg: 17%

13%
patients receiving schedule three controlled substances

Avg: 8%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 17%

$234
Average prescription price

Avg: $363

SOUNDAR RAJAN MD FACP

Hematology Oncology

3,069

$134K

233
88 are 65+

8%
patients receiving schedule two controlled substances

Avg: 17%

13%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 17%

$44
Average prescription price

Avg: $363

JOHN MUELLER M.D.

Hematology Oncology

2,936

$437K

217
195 are 65+

6%
patients receiving schedule two controlled substances

Avg: 17%

10%
patients receiving schedule three controlled substances

Avg: 8%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 17%

$149
Average prescription price

Avg: $363

ALBERTO BORGES M.D.

Hematology Oncology

2,892

$224K

160
141 are 65+

12%
patients receiving schedule two controlled substances

Avg: 17%

0%
patients receiving schedule three controlled substances

Avg: 8%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 17%

$77
Average prescription price

Avg: $363

LEROY ESSIG MD

Hematology Oncology

2,436

$297K

192
169 are 65+

10%
patients receiving schedule two controlled substances

Avg: 17%

10%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 17%

$122
Average prescription price

Avg: $363

PAUL RICHARDS M.D.

Hematology Oncology

1,887

$1.04M

234
196 are 65+

16%
patients receiving schedule two controlled substances

Avg: 17%

15%
patients receiving schedule three controlled substances

Avg: 8%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 17%

$549
Average prescription price

Avg: $363

JEROME GOLDSCHMIDT M.D.

Hematology Oncology

1,762

$756K

270
205 are 65+

17%
patients receiving schedule two controlled substances

Avg: 17%

16%
patients receiving schedule three controlled substances

Avg: 8%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 17%

$429
Average prescription price

Avg: $363

LLOYD SHABAZZ M.D.

Hematology Oncology

1,711

$895K

181
128 are 65+

23%
patients receiving schedule two controlled substances

Avg: 17%

25%
patients receiving schedule three controlled substances

Avg: 8%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 17%

$523
Average prescription price

Avg: $363

MAURA HAGAN M.D.

Hematology Oncology

1,579

$1.13M

264
223 are 65+

12%
patients receiving schedule two controlled substances

Avg: 17%

8%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 17%

$719
Average prescription price

Avg: $363

GORDON MORRIS MD

Hematology Oncology

1,520

$240K

191
173 are 65+

17%
patients receiving schedule two controlled substances

Avg: 17%

0%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 17%

$158
Average prescription price

Avg: $363

HARRY MCCOY M.D.

Hematology Oncology

1,508

$467K

269
212 are 65+

19%
patients receiving schedule two controlled substances

Avg: 17%

12%
patients receiving schedule three controlled substances

Avg: 8%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

24%
prescriptions for brand name drugs

Avg: 17%

$310
Average prescription price

Avg: $363

ELKE FRIEDMAN MD

Hematology Oncology

1,436

$1.04M

194
164 are 65+

13%
patients receiving schedule two controlled substances

Avg: 17%

11%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 17%

$724
Average prescription price

Avg: $363

WILLIAM FINTEL M.D.

Hematology Oncology

1,378

$613K

242
187 are 65+

16%
patients receiving schedule two controlled substances

Avg: 17%

10%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 17%

$445
Average prescription price

Avg: $363

ROBERT ROTCHE M.D.

Hematology Oncology

1,362

$347K

222
173 are 65+

20%
patients receiving schedule two controlled substances

Avg: 17%

21%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

9%
prescriptions for brand name drugs

Avg: 17%

$255
Average prescription price

Avg: $363

JOSEPH EVERS M.D.

Hematology Oncology

1,354

$459K

192
161 are 65+

21%
patients receiving schedule two controlled substances

Avg: 17%

14%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 17%

$339
Average prescription price

Avg: $363

SUZAN MERTEN M.D.

Hematology Oncology

1,316

$524K

209
157 are 65+

9%
patients receiving schedule two controlled substances

Avg: 17%

8%
patients receiving schedule three controlled substances

Avg: 8%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 17%

$398
Average prescription price

Avg: $363

CRAIG SWAINEY MD

Hematology Oncology

1,288

$189K

157
102 are 65+

38%
patients receiving schedule two controlled substances

Avg: 17%

17%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 17%

$147
Average prescription price

Avg: $363

SREEDHAR KATRAGADDA MD

Hematology Oncology

1,277

$712K

187
142 are 65+

17%
patients receiving schedule two controlled substances

Avg: 17%

12%
patients receiving schedule three controlled substances

Avg: 8%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 17%

$558
Average prescription price

Avg: $363

MARK CURRIE M.D.

Hematology Oncology

1,277

$889K

163
140 are 65+

10%
patients receiving schedule two controlled substances

Avg: 17%

17%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

25%
prescriptions for brand name drugs

Avg: 17%

$697
Average prescription price

Avg: $363

NICHOLAS GEMMA M.D.

Hematology Oncology

1,267

$492K

165
132 are 65+

11%
patients receiving schedule two controlled substances

Avg: 17%

0%
patients receiving schedule three controlled substances

Avg: 8%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 17%

$388
Average prescription price

Avg: $363

DARYL PIERCE MD

Hematology Oncology

1,265

$190K

251
177 are 65+

20%
patients receiving schedule two controlled substances

Avg: 17%

11%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

14%
prescriptions for brand name drugs

Avg: 17%

$150
Average prescription price

Avg: $363

BRIAN ROBINSON MD

Hematology Oncology

1,262

$375K

164
131 are 65+

15%
patients receiving schedule two controlled substances

Avg: 17%

0%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

11%
prescriptions for brand name drugs

Avg: 17%

$297
Average prescription price

Avg: $363

MATTHEW SKELTON MD

Hematology Oncology

1,223

$521K

174
129 are 65+

16%
patients receiving schedule two controlled substances

Avg: 17%

20%
patients receiving schedule three controlled substances

Avg: 8%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

24%
prescriptions for brand name drugs

Avg: 17%

$426
Average prescription price

Avg: $363

NEIL SCHACHT MD

Hematology Oncology

1,209

$299K

187
146 are 65+

28%
patients receiving schedule two controlled substances

Avg: 17%

0%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

11%
prescriptions for brand name drugs

Avg: 17%

$248
Average prescription price

Avg: $363

MAURICE SCHWARZ M.D.

Hematology Oncology

1,209

$672K

186
149 are 65+

24%
patients receiving schedule two controlled substances

Avg: 17%

10%
patients receiving schedule three controlled substances

Avg: 8%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 17%

$556
Average prescription price

Avg: $363

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank